Page last updated: 2024-11-12

brimonidine tartrate, timolol maleate drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Brimonidine Tartrate, Timolol Maleate Drug Combination: A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11387895
SCHEMBL ID5873369
MeSH IDM000603237

Synonyms (14)

Synonym
952743-07-6
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
brimonidine tartrate, timolol maleate drug combination
brimonidine tartrate / timolol maleate
combigan
brimonidine / timolol
brimonidine tartrate and timolol maleate
2-propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (2s)-, mixt. with 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-6-quinoxalinamine
SCHEMBL5873369
brimonidine/timolol
1-(tert-butylamino)-3-{[4-(morpholin-4-yl)-1,2,5-thiadiazol-3-yl]oxy}propan-2-ol--5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine (1/1)
DTXSID20915041
Q4968132
5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.81 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies2 (20.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor [NCT02623023]0 participants (Actual)Interventional2019-01-01Withdrawn(stopped due to Terminated prior to enrollment, lack of support.)
[NCT00822055]Phase 4140 participants (Actual)Interventional2005-05-31Completed
[NCT00822081]Phase 4140 participants (Actual)Interventional2005-01-31Completed
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter [NCT02214680]Phase 225 participants (Anticipated)Interventional2015-10-31Not yet recruiting
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients [NCT06078592]Phase 460 participants (Actual)Interventional2021-10-08Completed
The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema [NCT02718547]25 participants (Anticipated)Interventional2017-03-26Recruiting
An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension. [NCT00442312]Phase 443 participants Interventional2006-05-31Active, not recruiting
Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan in Subjects With Open Angle Glaucoma or Ocular Hypertension [NCT03235232]Phase 3384 participants (Anticipated)Interventional2021-02-01Recruiting
[NCT01987752]732 participants (Actual)Observational2009-01-31Completed
Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension [NCT02167035]Phase 443 participants (Actual)Interventional2014-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01987752 (2) [back to overview]Percentage of Participants Reporting Adverse Events
NCT01987752 (2) [back to overview]Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
NCT02167035 (2) [back to overview]Intraocular Pressure
NCT02167035 (2) [back to overview]Ocular Symptom and Tolerability Questionaire

Percentage of Participants Reporting Adverse Events

An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. (NCT01987752)
Timeframe: Up to 2.6 Years

InterventionPercentage of participants (Number)
Combigan® Ophthalmic Solution6.56

[back to top]

Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)

IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported. (NCT01987752)
Timeframe: Baseline, Week 4

InterventionPercentage of participants (Number)
Combigan® Ophthalmic Solution85.69

[back to top]

Intraocular Pressure

The Intraocular Pressure will be assessed on study subjects. IOP (Intraocular Pressure) will be measured using a Goldmann applanation tonometer. Both eyes will be tested, with the right eye preceding the left eye. The operator will initially set the dial at 10 mmHg, then look through the slit lamp and adjust the dial to take the reading, and then record the results. The procedure will be repeated on the same eye twice consecutively. If the measurements are within 2mmHg or less of each other, the mean of the 2 reading will be reported as the IOP at that time point. If the 2 reading are more than 2mmHg apart from each other, a third (consecutive) reading will be taken and the median (middle) IOP will be reported as the IOP at that time point. Preferable, the same operator will measure IOP and the same tonometer will be used at each visit. (NCT02167035)
Timeframe: Day 0 (08:00, 10:00 16:00), Day 30 (08:00, 10:00, 16:00), Day 90 (08:00, 10:00,16:00)

,
InterventionmmHg (Mean)
Baseline 8am IOPBaseline 10am IOPBaseline 4pm IOPBaseline Diurnal IOPVisit 3 8am IOPVisit 3 10am IOPVisit 3 4pm IOPVisit 3 Diurnal IOPVisit 4 8am IOPVisit 4 10am IOPVisit 4 4pm IOPVisit 4 Diurnal IOP
Combigan BID19.719.117.618.817.617.617.117.418.717.718.118.1
Simbrinza TID18.118.817.618.117.416.217.617.018.418.117.618.0

[back to top]

Ocular Symptom and Tolerability Questionaire

The secondary endpoint of this study was to determine the tolerability of each treatment group by utilizing ocular symptom questionnaires administered at each study visit. These questionnaires assessed Oral effects (bad taste, dry mouth) and Ocular comfort effects (itching, burning, stinging, burning on instillation, blurred vision). The scale proved was none=0, mild=1, moderate=2, severe=3. (NCT02167035)
Timeframe: Baseline (Day 0), Visit 2 (Day 7), Visit 3 (Day 30), Visit 4 (Day 90)

,
Interventionunits on a scale (Mean)
Baseline - Burning/Stinging Upon InstillationBaseline - non-instillation Burning/stingingBaseline - Dry/Gritty EyeBaseline - Foreign Body SensationBaseline - Eye RednessBaseline - Blurred VisionBaseline - Dry MouthBaseline - Bad Taste/change of tasteBaseline - HeadacheBaseline - Fatigue MalaiseVisit 2- Burning/Stinging Upon InstillationVisit 2- Non-Instillation Burning/StingingVisit 2- Dry/Gritty EyeVisit 2- Foreign Body SensationVisit 2- Eye RednessVisit 2- Blurred VisionVisit 2- Dry MouthVisit 2- Bad Taste/Change of TasteVisit 2- HeadacheVisit 2- Fatique MalaiseVisit 3- Burning/Stinging Upon InstillationVisit 3- Non-Instillation Burning/StingingVisit 3- Dry/Gritty EyeVisit 3- Foreign Body SensationVisit 3- Eye RednessVisit 3- Blurred VisionVisit 3- Dry MouthVisit 3- Bad Taste/Change of TasteVisit 3- HeadacheVisit 3- Fatigue MalaiseVisit 4- Burning/Stinging Upon InstillationVisit 4- Non-Instillation Burning/StingingVisit 4- Dry/Gritty EyeVisit 4- Foreign Body SensationVisit 4- Eye RednessVisit 4- Blurred VisionVisit 4- Dry MouthVisit 4- Bad Taste/Change of TasteVisit 4- HeadacheVisit 4- Fatigue Malaise
Combigan BID0.10.10.30.10.10.10.20.00.10.20.020.00.10.10.10.00.20.00.00.10.40.10.20.10.10.00.20.00.10.00.40.00.20.00.20.10.40.00.00.0
Simbrinza TID0.10.10.40.10.20.30.00.00.10.10.20.10.20.10.10.20.30.30.00.00.30.10.30.00.00.00.60.40.00.10.60.10.40.10.20.10.40.30.10.1

[back to top]